These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 37787311)
1. Treating low- and intermediate-risk acute promyelocytic leukemia with and without chemotherapy: A comparison in a tertiary care center. Saxena M; Madabhavi IV; Patel A; Panchal H; Anand A J Cancer Res Ther; 2023; 19(5):1371-1378. PubMed ID: 37787311 [TBL] [Abstract][Full Text] [Related]
3. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D; Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238 [TBL] [Abstract][Full Text] [Related]
4. [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis]. Xu SN; Chen JP; Liu JP; Xia Y Zhong Xi Yi Jie He Xue Bao; 2009 Nov; 7(11):1024-34. PubMed ID: 19912733 [TBL] [Abstract][Full Text] [Related]
5. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. Lo-Coco F; Avvisati G; Vignetti M; Thiede C; Orlando SM; Iacobelli S; Ferrara F; Fazi P; Cicconi L; Di Bona E; Specchia G; Sica S; Divona M; Levis A; Fiedler W; Cerqui E; Breccia M; Fioritoni G; Salih HR; Cazzola M; Melillo L; Carella AM; Brandts CH; Morra E; von Lilienfeld-Toal M; Hertenstein B; Wattad M; Lübbert M; Hänel M; Schmitz N; Link H; Kropp MG; Rambaldi A; La Nasa G; Luppi M; Ciceri F; Finizio O; Venditti A; Fabbiano F; Döhner K; Sauer M; Ganser A; Amadori S; Mandelli F; Döhner H; Ehninger G; Schlenk RF; Platzbecker U; ; ; N Engl J Med; 2013 Jul; 369(2):111-21. PubMed ID: 23841729 [TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial. Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214 [TBL] [Abstract][Full Text] [Related]
7. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia. Quezada G; Kopp L; Estey E; Wells RJ Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388 [TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia. Chen L; Wang J; Hu X; Xu X Hematology; 2014 Jun; 19(4):202-7. PubMed ID: 24074286 [TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States. Tallman M; Lo-Coco F; Barnes G; Kruse M; Wildner R; Martin M; Mueller U; Tang B Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):771-7. PubMed ID: 26361645 [TBL] [Abstract][Full Text] [Related]
10. All-Trans Retinoic Acid plus Arsenic Trioxide versus All-Trans Retinoic Acid plus Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia: A Meta-Analysis. Ma Y; Liu L; Jin J; Lou Y PLoS One; 2016; 11(7):e0158760. PubMed ID: 27391027 [TBL] [Abstract][Full Text] [Related]
11. Chemotherapy-free approaches to newly-diagnosed acute promyelocytic leukaemia: is oral-arsenic trioxide/all-trans retinoic acid/ascorbic acid the answer? Gill H Expert Rev Hematol; 2024 Oct; 17(10):661-667. PubMed ID: 39120131 [TBL] [Abstract][Full Text] [Related]
12. What is the standard regimen for patients with acute promyelocytic leukemia? Lo-Coco F; Cicconi L Curr Hematol Malig Rep; 2014 Jun; 9(2):138-43. PubMed ID: 24729066 [TBL] [Abstract][Full Text] [Related]
13. An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial). Wang HY; Gong S; Li GH; Yao YZ; Zheng YS; Lu XH; Wei SH; Qin WW; Liu HB; Wang MC; Xi JY; Chen LM; Zhang M; Zhang XX; Zhang HY; Zhang CS; Wald DN; Zhu HH; Liu L; He PC Blood Cancer J; 2022 Nov; 12(11):158. PubMed ID: 36404343 [TBL] [Abstract][Full Text] [Related]
14. Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide. Shepshelovich D; Oniashvili N; Parnes D; Klein A; Muchtar E; Yeshaya J; Aviram A; Rabizadeh E; Raanani P Cancer Genet; 2015 Nov; 208(11):575-9. PubMed ID: 26471811 [TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Hu J; Liu YF; Wu CF; Xu F; Shen ZX; Zhu YM; Li JM; Tang W; Zhao WL; Wu W; Sun HP; Chen QS; Chen B; Zhou GB; Zelent A; Waxman S; Wang ZY; Chen SJ; Chen Z Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3342-7. PubMed ID: 19225113 [TBL] [Abstract][Full Text] [Related]
16. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642 [TBL] [Abstract][Full Text] [Related]